Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026 and took note of disclosure of interest received under section 184 and 164, ....
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 29 Jul 2026, 04:43 PM IST · BSE ID: e2af311d-503f-47e5-bc64-fe6370f32d9c
View Original BSE Filing (PDF)
💡
In Simple Terms
Vivanta Industries approved its quarterly financial results and noted a new partnership in the pharmaceutical business.
🤖 AI Summary
- Vivanta Industries board approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026.
- The board noted execution of a business collaboration agreement with Qness Pharmaceuticals for pharmaceutical product activities.
- Directors' disclosures of interest under Section 184 and disqualification under Section 164 of the Companies Act, 2013 were noted.
- Authorisation was approved for opening a Trading and Demat Account with Motilal Oswal Financial Services Limited for the company.
- The board also noted the issuance of duplicate share certificate(s) to Mr. Rajesh Bhanji Lakum due to loss/misplacement.
🏢 How This Affects the Company
The noting of a business collaboration with Qness Pharmaceuticals could expand Vivanta Industries' operations into the pharmaceutical sector, covering manufacture, supply, branding, and marketing. This introduces a new business vertical for the company.
The authorization of designated signatories to open a Trading Account and Demat Account with Motilal Oswal Financial Services Limited provides new avenues for company financial operations. The collaboration with Qness Pharmaceuticals suggests an expansion of operational scope.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are indirectly affected by the company's strategic decision to potentially expand into the pharmaceutical business through the noted collaboration.
🔍
Management Signal
Management is signaling an intent to diversify or expand the company's business operations into the pharmaceutical sector and maintain robust corporate governance practices.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Release of detailed Q1 FY27 financial results to assess performance metrics.
Further announcements detailing the scope and terms of the Qness Pharmaceuticals collaboration.
Updates on the operationalization and financial contribution of the pharmaceutical business.
LOW RISK
The filing details routine board approvals and notes a business collaboration without specifying immediate financial commitments or risks.
💡 Investor Takeaway
Vivanta Industries' board approved Q1 FY27 Unaudited Standalone and Consolidated Financial Results. A business collaboration with Qness Pharmaceuticals for pharmaceutical product activities was noted, signaling a new business avenue for the company.
⚖️ Strengths & Concerns
✅ Positives
- Board's approval of Unaudited Standalone and Consolidated Financial Results for Q1 FY27 maintains regulatory compliance for financial reporting.
- Noting of a business collaboration with Qness Pharmaceuticals expands Vivanta Industries into pharmaceutical manufacture, supply, and marketing.
📅 Company Track Record
Vivanta Industries previously approved its Q1 FY27 results and a new pharmaceutical business collaboration on 2026-07-29, which this filing reaffirms and details as 'noted the execution'.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What financial results did Vivanta Industries' board approve?
Vivanta Industries' board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026.
What new business collaboration did Vivanta Industries' board note?
The board noted the execution of certain business collaboration agreements with Qness Pharmaceuticals for the manufacture, supply, branding, and marketing of pharmaceutical and allied products.
What financial account changes did Vivanta Industries' board approve?
The board approved the authorisation of designated signatories to open a Trading Account and Demat Account with Motilal Oswal Financial Services Limited on behalf of the Company.
Which shareholder received a duplicate share certificate from Vivanta Industries?
The board noted the issuance of duplicate share certificate(s) to Mr. Rajesh Bhanji Lakum in lieu of original certificates reported as lost/misplaced.
Questions based on this BSE filing only. For information purposes.